ER+ breast tumor response to alternating 17b-estradiol and aromatase inhibitor therapies
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
Patients with ER+ breast cancer were treated with an alternating schedule of 17b-estradiol (8 weeks) and aromatase inhibitor (16 weeks) until disease progression. Tumor specimens acquired prior to study treatment were used for exome sequencing.
创建时间：
2022-09-12
